Mafepain

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mafepain

Quick Facts

Property Description
Active Ingredient Mefenamic Acid
Form Tablets and capsules (solid oral forms)
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Use Symptomatic relief of pain, inflammation, and fever
Origin Synthetic, anthranilic acid derivative

What Type of Medicine is Mafepain?

Mafepain is a prescription-only medication that belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, primarily utilized for the relief of mild to moderate symptoms involving pain, inflammation, and fever. Its core active substance is Mefenamic Acid, which is chemically defined as a fenamate and specifically as an anthranilic acid derivative. This chemical classification sets its structure apart from other NSAID subgroups. The use of this drug for short-term symptomatic relief is clinically recognized across multiple jurisdictions.


Mefenamic Acid: Composition, Origin, and Form

The active ingredient, Mefenamic Acid, is a synthetic small molecule, manufactured as a single active ingredient product. Mafepain is prepared for oral administration and is commonly supplied as a solid oral form, typically as film-coated tablets or capsules. This oral route facilitates its intended systemic delivery, which is necessary for treating widespread discomfort. The medicine’s composition focuses the therapeutic effect exclusively on the properties of Mefenamic Acid.


What is the General Purpose of Mafepain?

The general purpose of Mafepain is to provide symptomatic relief by exhibiting three main physiological actions: it is an analgesic (pain reliever), an anti-inflammatory agent (reducing swelling and irritation), and an antipyretic (fever reducer). It achieves these effects by functioning as a Cyclooxygenase Inhibitor, blocking the production of key local hormone-like substances called prostaglandins that are responsible for initiating and propagating pain and inflammation signals throughout the body. The inhibition of prostaglandins is the core mechanism by which this medicine reduces the body's acute inflammatory and pain response.

What side effects are possible with Mafepain?

Possible Side Effects and Safety Information: Mafepain

Mafepain (Mefenamic Acid) is a nonsteroidal anti-inflammatory drug (NSAID) used for short-term pain relief. Like all medications, it can cause side effects, though not everyone experiences them. It is important to be aware of the serious risks associated with NSAIDs.


Serious Warnings

This medication carries a risk of serious, potentially fatal, cardiovascular thrombotic events (such as heart attack and stroke), particularly with long-term use or in people with pre-existing heart disease. It can also increase the risk of serious gastrointestinal side effects, including bleeding, ulcers, and perforation of the stomach or intestines, which can occur without warning. If you have had recent coronary artery bypass graft (CABG) surgery, you should not take Mafepain.


Common Side Effects

The most commonly reported side effects typically involve the gastrointestinal system and include:

  • Diarrhea
  • Nausea, vomiting, and upset stomach
  • Abdominal pain or discomfort
  • Gas and bloating

Less frequent but reported side effects include headache, dizziness, and ringing in the ears (tinnitus).


When to Seek Immediate Medical Attention

Stop taking Mafepain and seek emergency medical help if you experience signs of a serious reaction, including:

  • Signs of GI Bleeding: Bloody or black, tarry stools, or vomiting material that looks like coffee grounds.
  • Signs of Allergic Reaction: Rash, hives, swelling of the face, lips, tongue, or throat, or difficulty breathing.
  • Signs of Heart/Stroke Problems: Chest pain, sudden weakness on one side of the body, or slurred speech.
  • Signs of Liver Problems: Yellowing of the skin or eyes (jaundice), dark urine, or upper right stomach pain.

It is essential to discuss your full medical history with your healthcare provider before starting Mafepain, especially if you have a history of heart disease, bleeding disorders, high blood pressure, asthma, or kidney/liver impairment. Do not take this medication for longer than prescribed by your doctor.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations of Mafepain (Mefenamic Acid) overdose and the emergency actions required by regulatory authorities. The information is strictly derived from government prescribing information and official drug safety reports.


Documented Manifestations and Severe Outcomes

Official regulatory documents state that acute overdosage of Mefenamic Acid may present with central nervous system (CNS) effects, including convulsions (seizures), drowsiness, headache, and confusion. Gastrointestinal manifestations commonly observed include nausea, vomiting, and epigastric pain. Severe outcomes documented in official labeling include acute renal failure, hypotension (low blood pressure), and the potential for gastrointestinal hemorrhage.

Elderly patients are noted in official labeling as being potentially less tolerant of complications like gastrointestinal bleeding.


Official Emergency Actions and Management

Immediate emergency medical attention must be sought if an overdose is suspected. Government guidance requires contacting emergency services immediately if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Regulatory information confirms that no specific antidote for Mefenamic Acid overdose is known. Management focuses entirely on symptomatic and supportive care. Procedures such as the use of activated charcoal or gastric lavage may be considered by medical professionals following a recent, significant ingestion.

Therapeutic Uses of Mafepain

What Mafepain Treats: Main Uses and Benefits

Mafepain (Mefenamic Acid) is applied across domains where additional symptomatic support is needed, addressing symptoms related to physical discomfort or heightened physiological activity. It is commonly used when symptoms that interfere with daily functioning become more noticeable, offering short-term symptomatic assistance. The therapeutic role of Mafepain is aligned with official guidelines for symptomatic management.


Mafepain is relevant for easing symptoms in conditions involving episodic or fluctuating manifestations, such as menstrual discomfort (primary dysmenorrhea) and symptoms related to heavy menstrual bleeding (menorrhagia). It helps address symptom clusters that may become intense, such as acute pain following procedures like dental work or from traumatic strains, and is applied in addressing chronic conditions like rheumatoid arthritis and osteoarthritis. Furthermore, it is relevant for managing general symptoms related to systemic imbalance, including fever, headaches, and muscular discomfort. This supportive use helps ease the overall symptom load and contributes to improved comfort during symptomatic periods.

Quick Fact: Symptom Management Overview
Therapeutic Scope: Symptomatic management of mild to moderate pain, inflammation, and fever (antipyresis).
Relevant Contexts: Cyclical menstrual pain, post-traumatic or post-procedural pain, and musculoskeletal flare-ups.
Contributes to: Supports coping with distressing symptoms and assists with maintaining functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Mafepain?

The population eligibility for Mafepain (Mefenamic Acid) is strictly defined by regulatory documents, primarily based on age, organ function, and a patient's pre-existing conditions.

Contraindications and Non-Eligibility

Mafepain must not be used by individuals with a known hypersensitivity to the medicine or a history of allergic-type reactions (such as asthma or hives) after taking aspirin or other NSAIDs. Absolute contraindications also include severe uncontrolled heart failure, severe hepatic failure, significantly impaired renal function, or active ulceration or chronic inflammation of the gastrointestinal tract.

Use is prohibited for patients undergoing treatment for peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery.

Age and Physiological Constraints

Population Eligibility Status (Regulatory Wording)
Age 14 Years and Older Established for use
Children Under 14 Safety and efficacy have not been established
Third Trimester Pregnancy Contraindicated
Breastfeeding Not recommended
Elderly Patients Use requires caution and monitoring

Patients with conditions like pre-existing hypertension or those prone to fluid retention require special consideration and close supervision during use.

What should I know about interactions with other medicines?

Mafepain’s interaction profile is based on pharmacodynamic and pharmacokinetic principles, leading to specific mandatory constraints documented in regulatory labeling.

Interaction Restrictions and Timing

Co-administration with other systemic non-aspirin NSAIDs is officially avoided due to the compounded risk of serious gastrointestinal events, including bleeding and ulceration. Use with oral anticoagulants is contraindicated if close and continuous monitoring of prothrombin time is not available, as Mafepain enhances the bleeding risk. Furthermore, a strict timing separation is required for Mifepristone; Mafepain must not be taken for 8–12 days following its administration.

Official Interaction Mechanisms

Mafepain has documented pharmacodynamic interactions that result in a reduction of the therapeutic efficacy of Antihypertensives (e.g., ACE inhibitors, Diuretics). It also carries an additive risk of bleeding when combined with anti-platelet agents and SSRIs.

Exposure and Metabolic Impacts

Pharmacokinetic interactions include Mafepain reducing the elimination or clearance of medicines such as Lithium and Methotrexate, thereby increasing their plasma concentrations. Mafepain also acts as an inhibitor of the metabolism of sulfonylurea-type oral hypoglycaemic agents, which increases the official risk of hypoglycemia. Antacids containing magnesium hydroxide significantly increase Mafepain's own absorption and exposure. Interactions with alcohol and tobacco are noted to increase the risk of serious gastrointestinal events.

Population Considerations

The potential for renal function deterioration, when Mafepain is co-administered with certain blood pressure medications, is explicitly highlighted for elderly and dehydrated patients in the prescribing information.

Mechanism of Action

How Mafepain Works

Mafepain operates through a targeted mechanism, modulating specific biological processes and influencing core signaling pathways. Its action is concentrated across distinct mechanistic domains.

Specific Receptor and Enzyme Modulation

Mafepain initiates its effect by acting on defined biological targets, such as key receptors or enzymes, within relevant regulatory systems. This primary interaction modulates the activity of these molecules, which are often overactive or dysregulated, thereby controlling the initial input into the signaling cascade.

Dampening of Overactive Signaling Cascades

The drug engages with specific signal transduction cascades to reduce heightened pathway activation. By suppressing or normalizing these sequences, Mafepain limits the downstream effects and the spread of excessive or sustained signaling across neural or humoral systems.

Regulation of Dysregulated Physiological Responses

The overall mechanism involves the regulation of overactive or unstable physiological processes. By restoring a more balanced activity within targeted pathways, Mafepain's action on targeted pathways results in a modulation of physiological activity.

Dosage and Administration Information

How to Use Mafepain: Official Administration Guidelines

Mafepain (Mefenamic Acid) is administered by the oral route only, primarily supplied as capsules or tablets. The official instructions for its use establish a short-term, intermittent treatment protocol that dictates dosage, frequency, and duration.


Standard Dosing Regimen

The regimen for adults (14 years of age and older) begins with a higher initial dose followed by a fixed maintenance schedule.

Instruction Entity Regulatory Guideline
Initial Dose 500 mg taken once.
Maintenance Dose 250 mg taken every 6 hours (four times daily).
Maximum Daily Dose The total daily dose must not exceed 1500 mg.

Administration Conditions and Duration

Mafepain is mandated for short-term use and should not be taken continuously. The duration for general acute pain is usually not to exceed 7 days. For indications like primary dysmenorrhea, the medicine is typically used only for the first 2 to 3 days of the menstrual cycle.

The medicine should be taken with food or with milk to ensure proper intake conditions. Tablets and capsules must be swallowed whole with water to ensure correct dosing. If a dose is missed, instructions for use suggest to skip the missed dose if the next scheduled dose is near, and to not double the dose to catch up.

For older adults, the official instruction emphasizes the use of the lowest effective dose for the shortest possible duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mafepain

Mafepain (Mefenamic Acid) was studied for its use in research exploring symptom patterns across several conditions characterized by fluctuating or episodic manifestations. The research base involves various study types, including short-term, controlled trials and systematic reviews, which explore outcomes related to physical discomfort and functional imbalance.

Evidence for Research on Cyclical Pain Patterns (Primary Dysmenorrhea and Menorrhagia)

The evidence for the use of Mafepain in research related to the menstrual cycle primarily consists of short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies explored outcomes related to physical discomfort, focusing on populations diagnosed with primary dysmenorrhea (menstrual pain) or menorrhagia (heavy menstrual bleeding).

Researchers examined patient-reported outcomes describing perceived discomfort, such as pain intensity scores. Studies explored short-term symptom changes, tracking patterns of symptom evolution across a limited number of consecutive menstrual cycles. What remains uncertain is the applicability of these findings to secondary dysmenorrhea. Follow-up durations were limited to the short, cyclical nature of the condition, meaning there is limited information on the long-term pattern of observed symptom changes over many years.

Evidence for Research on Short-Term Acute Pain Patterns

Research has also explored Mafepain's use for acute, mild to moderate pain, such as post-operative or dental pain models used in the research setting. The available evidence includes controlled trials and systematic reviews that focused on outcomes describing episodic or acute changes in symptom intensity.

Studies monitored pain relief scores and the time required until participants used supplemental pain medication. Data show patterns related to how symptom scores evolved over the initial hours following a single dose. Follow-up durations were limited to very short courses, often measured in hours or up to seven days. Therefore, long-term outcomes are not fully established for ongoing or recurring acute symptom patterns, and the results apply only to the populations studied under these short-term regulatory constraints.

Evidence in Specific Patient Groups and Antipyresis

Research examined the use of Mafepain in specific groups, including its role as an antipyretic (fever reducer). Mafepain was studied for its use in research exploring temporary physiological imbalance, specifically fever, comparing its antipyretic activity to other common fever-reducing substances. While research describes patterns where fever reduction was measured, data for certain groups remain insufficient. Generally, outcomes and risk profiles have not been established in the pediatric population (under 14 or 18 years of age, depending on the jurisdiction) for indications other than those specifically researched.

Key Studies & References Mefenamic Acid Capsules Official FDA Label Information (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Mafepain (FAQ)

Q: Can Mafepain be used for chronic pain management?

Official regulatory guidance limits the use of Mafepain to short-term, intermittent treatment protocols. According to product information, it is not intended for the management of chronic (long-term) conditions, and treatment duration for general acute pain is usually not to exceed seven days.


Q: How is Mafepain different from regular over-the-counter pain pills?

Mafepain is classified as a prescription-only medicine, meaning its use requires authorization from a healthcare provider. Chemically, it belongs to a specific NSAID subgroup known as fenamates, which differentiates it from some common over-the-counter pain relievers like ibuprofen.


Q: Does Mafepain cause long-term kidney problems?

As with other medicines in its class (NSAIDs), official regulatory documents note the potential for renal dysfunction (kidney problems). These risks are typically associated with use over prolonged periods. According to official regulatory documents, use is contraindicated for patients with significantly impaired renal function.


Q: Does Mafepain interact with any specific foods or drinks?

Administration instructions state that Mafepain is to be taken with food or milk to ensure proper intake conditions. Additionally, official warnings note that consuming alcohol while taking the medicine may increase the risk of serious gastrointestinal side effects.


Q: Is there an interaction described between Mafepain and aspirin?

Official documents note that Mafepain may interfere with the anti-blood clotting effects of aspirin and other anti-platelet agents, which increases the documented risk of serious bleeding events.


Q: How long does one dose of Mafepain last?

While the exact duration of symptom relief varies by person, official instructions establish a maintenance dosing schedule of typically every 6 hours for approved indications. Pharmacokinetic data from official sources indicates that the elimination half-life is approximately two hours.


Q: What should I expect the first few days of taking Mafepain?

Mafepain is intended to provide symptomatic relief for the approved short-term conditions, such as acute pain or menstrual discomfort. Studies have examined patient-reported outcomes to track how quickly the medication modulates symptoms like pain intensity and functional imbalance.


Q: Does Mafepain work immediately for everyone?

Clinical trial data indicates that patient response to Mafepain may vary. Official information describes that not all individuals respond to the treatment with the same outcome or speed.


Q: Can people with high blood pressure use Mafepain?

Official guidance notes that individuals with pre-existing hypertension (high blood pressure) or those prone to fluid retention require special consideration. The prescribing information indicates the need for close supervision in these populations.


Q: Is there a large body of research supporting Mafepain's approved use?

The approved uses of Mafepain are supported by a research base that includes short-term, controlled clinical trials and systematic reviews. These studies have examined patient outcomes related to its approved indications, such as cyclical pain and acute short-term pain.


Q: What do the clinical trials say about how Mafepain works?

Clinical trials primarily focus on measuring the effect of the medicine, such as changes in patient-reported discomfort and symptom scores. These observed outcomes align with the known mechanism of action, which is described as functioning as a Cyclooxygenase Inhibitor to reduce pain signals.


Q: What is the main difference between Mafepain and ibuprofen?

Both Mafepain and ibuprofen are classified as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). However, Mafepain belongs to a different chemical subgroup known as fenamates and is legally classified as a prescription-only medicine.


Q: Does official guidance mention driving or operating machinery while on Mafepain?

Regulatory guidance states that undesirable effects such as dizziness, drowsiness, fatigue, and visual disturbances have been reported. If a patient is affected by these effects, driving or operating machinery is not recommended in the official product labeling.


Q: How does Mafepain compare to the placebo in clinical trials?

Studies comparing Mafepain to an inactive substance (placebo) for acute pain and dysmenorrhea showed that the drug demonstrated a statistical difference in pain scores compared to the placebo control.


Q: Is it common to feel tired when taking Mafepain?

Tiredness or unusual fatigue is not typically listed among the most commonly reported side effects. Regulatory documents do cite it as a possible symptom that may accompany more serious conditions, such as anemia or liver problems, which are addressed in the serious warnings section.


Q: Can taking Mafepain affect my mood or sleep?

Regulatory documents report drowsiness (somnolence) and nervousness as possible side effects. Adverse effects like changes to mood or difficulty sleeping (insomnia) are not typically listed among the most frequently reported reactions.


Q: Are there any reported withdrawal symptoms described for Mafepain?

Since Mafepain is not classified as a controlled substance, there is no specific information detailed in the official prescribing documents concerning withdrawal symptoms associated with stopping the medication.


Q: Is there a risk of becoming dependent on Mafepain?

Mafepain is a prescription-only medicine and is not classified as a controlled substance under the US DEA scheduling system. This classification is determined by regulatory bodies based on the drug's potential for abuse or dependence and differentiates it from controlled substances.


Q: Is it okay to take Mafepain with vitamins or supplements?

Official regulatory information states that you should inform your healthcare provider about all medicines, including any vitamins and herbal supplements, before taking Mafepain. This is necessary because many products can affect how the drug works.


Q: How does Mafepain interact with birth control pills?

Mafepain has been noted to interact with specific types of oral contraceptives, particularly those that contain the ingredient drospirenone. The prescribing information indicates that caution is necessary and that monitoring may be necessary if these are used concurrently.


Q: Can I take Mafepain with other pain relievers like acetaminophen?

Official regulatory documents indicate that there is no stated contraindication listed against using Mafepain concurrently with acetaminophen (paracetamol), as they operate through different mechanisms of action.


Q: What is the general guidance on Mafepain and herbal remedies?

Official regulatory information states that you should inform your healthcare provider about all medicines, including any vitamins and herbal supplements, before taking Mafepain. This is necessary because many products can affect how the drug works.


Q: How fast does Mafepain start working?

Mafepain is described as being rapidly absorbed after it is taken orally. Pharmacokinetic studies indicate that the concentration generally reaches its highest level in the bloodstream between two and four hours after administration.


Q: Where can I find the official prescribing information for Mafepain?

Official regulatory information is contained in the Patient Information Leaflet (PIL) that comes with the medicine. This information can also be found on government websites that host drug labels, such as DailyMed (US) or the SmPC (Europe).


Q: Is Mafepain considered a controlled substance?

Mafepain is a prescription-only medicine and is not classified as a controlled substance under the US DEA scheduling system. This classification is determined by regulatory bodies based on the drug's potential for abuse or dependence.

How should Mafepain be stored and disposed of?

Mafepain (Mefenamic Acid) must be stored and disposed of according to specific regulatory guidelines to ensure stability and public safety.

Official Storage Requirements

Temperature and Protection: Store the medicine at a temperature not exceeding 30 C and keep it from freezing. Mafepain must be protected from light and moisture and kept in the original container, tightly closed.

Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.

Regulatory Disposal Instructions

Unused or expired Mafepain should not be disposed of via wastewater or household waste. The recommended method is using an official drug take-back program. If a take-back option is unavailable, the product may be disposed of in the household trash by mixing it with an undesirable substance (like dirt or coffee grounds) and sealing the mixture in a container before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mafepain found in:

A-Z Index: